Article Details

INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Zacks Investment Research

Retrieved on: 2022-05-14 13:54:33

Tags for this article:

Click the tags to see associated articles and topics

INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Zacks Investment Research. View article details on HISWAI: https://www.defenseworld.net/2022/05/14/inmune-bio-nasdaqinmb-stock-rating-upgraded-by-zacks-investment-research.html

Excerpt

According to Zacks, “INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up